In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AgaMatrix Inc.

Latest From AgaMatrix Inc.

Diabetes Care A Prime Target For Amazon

Amazon's recent partnership with the Arcadia Group to supply blood glucose strips and meters under the new brand name Choice is another move by the retail giant to disrupt the health-care sector using the path of least resistance.

Business Strategies Commercial

Digital Health And Reimbursement Issues Divide Glucose Monitoring Market

Innovative technology from companies such as Google offers the promise of new digital health options in the glucose monitoring market, while drastic reimbursement cuts affecting existing meters and supplies in the US are taking a noticeable toll on the major players already operating in the field. These competing factors have created a dichotomy characterized by opportunity on one side and uncertainly on the other, and that is forcing some competitors to re-think their business strategies.

Consumer Medical Device

Biopharma Sizes Up The Affordable Care Act: Buyer’s Remorse Or Winner’s Curse?

Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.

BioPharmaceutical United States

On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes

With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.

BioPharmaceutical Launches
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Medical Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AgaMatrix Inc.
  • Senior Management
  • John Alberico, CEO
    Jackson McAdam, CFO
  • Contact Info
  • AgaMatrix Inc.
    Phone: (603) 328-6000
    7C Raymond Ave.
    Salem, NH 03079